The British Veterinary Association has issued an interim guidance document for member practitioners on how to handle the rising volume of owner inquiries about canine longevity drugs. The document does not endorse, recommend, or take a position on any specific compound; it specifically focuses on the conversation itself, recognizing that UK general practitioners are increasingly being asked questions they don't yet have authoritative answers for.

The guidance is structured around four core principles. First, validate the owner's interest — wanting to extend a dog's healthy lifespan is a legitimate concern and not something to dismiss or minimize. Second, distinguish clearly between investigational compounds and approved medications, and never imply that any current product available in the UK is a longevity drug. Third, emphasize foundational care — dental health, body condition, structured exercise, senior bloodwork — as the highest-leverage intervention available today. Fourth, point owners toward credible information sources rather than allowing the conversation to dead-end at "we don't know."

The document also includes practical scripting suggestions for common inquiry patterns: the owner who has read about a specific company in the news, the owner who is asking about supplements that claim longevity benefits, the owner who is considering personally importing investigational supply from a foreign access programme, and the owner whose dog has just received a difficult prognosis and is grasping for any intervention that might help.

This kind of guidance is unusual for the BVA to publish ahead of any actual approval, and the decision to do so reflects the volume of inquiries member practitioners have been reporting. Survey data referenced in the document indicates that UK general practitioners are now fielding longevity-related questions in roughly one in eight senior dog consultations — a rate that has roughly tripled in the last eighteen months.

For UK owners, the practical implication is that vets are now better equipped to have a substantive conversation about the topic, even though the prescribing pathway is still some time away. The conversation itself is increasingly worth having, particularly around the foundational care decisions that compound favourably with any future longevity intervention.